PT  - JOURNAL ARTICLE
AU  - Calabrese, Cassandra
AU  - Kirchner, Elizabeth
AU  - Fernandez, James
AU  - Calabrese, Leonard H.
TI  - Preventing herpes zoster in immunocompromised patients: Current concepts
AID  - 10.3949/ccjm.91a.24019
DP  - 2024 Jul 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 437--445
VI  - 91
IP  - 7
4099  - http://www.ccjm.org/content/91/7/437.short
4100  - http://www.ccjm.org/content/91/7/437.full
SO  - Cleve Clin J Med2024 Jul 01; 91
AB  - Herpes zoster (HZ) incidence is much higher in immunocompromised individuals than in immunocompetent individuals. HZ also occurs at a younger age and is often more severe in immunocompromised persons. Preventive strategies center around the recombinant zoster vaccine (RZV), which is approved for immunocompromised adults age 19 and older. Identifying those at greatest risk is critical. For those considering vaccination, evidence gaps regarding vaccine efficacy, toxicity, length of protection, and potential effects on underlying conditions may complicate shared and informed decision-making. Recent data have filled some of these gaps, with several societies issuing recommendations regarding vaccination. Remaining gaps are currently addressed by expert opinion.